Definitive Healthcare (NASDAQ:DH) Cut to Buy at Wall Street Zen

Definitive Healthcare (NASDAQ:DH) was downgraded by Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued on Sunday.

DH has been the subject of several other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Definitive Healthcare in a research report on Wednesday, October 8th. Canaccord Genuity Group dropped their price objective on shares of Definitive Healthcare from $5.00 to $4.00 and set a “hold” rating for the company in a report on Monday, November 10th. William Blair raised shares of Definitive Healthcare to a “strong-buy” rating in a research note on Thursday, November 6th. Barclays decreased their price target on shares of Definitive Healthcare from $3.00 to $2.75 and set an “underweight” rating for the company in a research report on Monday, December 8th. Finally, Morgan Stanley reaffirmed an “underperform” rating and set a $3.50 price objective on shares of Definitive Healthcare in a research report on Thursday, December 18th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have assigned a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, Definitive Healthcare presently has a consensus rating of “Hold” and a consensus price target of $3.94.

Definitive Healthcare Price Performance

Shares of DH opened at $2.63 on Friday. Definitive Healthcare has a twelve month low of $2.15 and a twelve month high of $5.68. The company has a market cap of $371.78 million, a price-to-earnings ratio of -1.57 and a beta of 1.60. The company has a 50 day moving average of $2.67 and a two-hundred day moving average of $3.44. The company has a quick ratio of 1.60, a current ratio of 1.60 and a debt-to-equity ratio of 0.41.

Definitive Healthcare (NASDAQ:DH) last posted its earnings results on Thursday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.01. The company had revenue of $60.05 million during the quarter, compared to analysts’ expectations of $59.51 million. Definitive Healthcare had a positive return on equity of 3.30% and a negative net margin of 77.88%.Definitive Healthcare has set its FY 2025 guidance at 0.230-0.240 EPS and its Q4 2025 guidance at 0.050-0.060 EPS. As a group, analysts predict that Definitive Healthcare will post 0.16 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Cambria Investment Management L.P. acquired a new stake in shares of Definitive Healthcare in the third quarter worth approximately $145,000. Ariadne Wealth Management LP purchased a new position in Definitive Healthcare during the third quarter worth approximately $54,000. PharVision Advisers LLC acquired a new position in shares of Definitive Healthcare in the 3rd quarter valued at $120,000. Prelude Capital Management LLC purchased a new stake in shares of Definitive Healthcare during the 3rd quarter valued at $64,000. Finally, Arrowstreet Capital Limited Partnership increased its holdings in shares of Definitive Healthcare by 11.7% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,216,007 shares of the company’s stock worth $4,937,000 after buying an additional 127,055 shares during the last quarter. Institutional investors and hedge funds own 98.67% of the company’s stock.

Definitive Healthcare Company Profile

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.